STOCK TITAN

Predictmedix AI Announces Closing of $100,000 Third Tranche with Strong Insider Participation and Launch of Smart Health AI Stations

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
AI

Predictmedix AI (CSE: PMED, OTC: PMEDF) has successfully closed the third and final tranche of its non-brokered private placement, raising $100,000 CAD. The placement saw strong insider participation, with $90,000 subscribed by insiders Sheldon Kales and Dr. Rahul Kushwah ($45,000 each).

The company issued 5,000,000 units at $0.02 per unit, with each unit comprising one common share and one purchase warrant. Warrants are exercisable at $0.05 per share for 24 months, with an acceleration clause if share prices exceed $0.10 for ten consecutive trading days.

Additionally, Predictmedix has begun fabrication of fifteen Smart Health AI Stations for strategic deployment, primarily targeting the United States market. The proceeds will support market expansion, with a focus on U.S. enterprise and government sectors.

Predictmedix AI (CSE: PMED, OTC: PMEDF) ha chiuso con successo la terza e ultima tranche del suo collocamento privato non mediato, raccogliendo 100.000 CAD. Il collocamento ha visto una forte partecipazione interna, con 90.000 sottoscritti da parte degli insider Sheldon Kales e Dr. Rahul Kushwah (45.000 ciascuno).

L'azienda ha emesso 5.000.000 di unità a 0,02 CAD per unità, con ciascuna unità composta da un'azione comune e un warrant d'acquisto. I warrant sono esercitabili a 0,05 CAD per azione per 24 mesi, con una clausola di accelerazione se i prezzi delle azioni superano 0,10 CAD per dieci giorni di negoziazione consecutivi.

Inoltre, Predictmedix ha iniziato la fabbricazione di quindici Stazioni Smart Health AI per un dispiegamento strategico, mirando principalmente al mercato degli Stati Uniti. I proventi supporteranno l'espansione del mercato, con un focus sui settori aziendali e governativi statunitensi.

Predictmedix AI (CSE: PMED, OTC: PMEDF) ha cerrado con éxito la tercera y última tranche de su colocación privada no mediada, recaudando 100,000 CAD. La colocación tuvo una fuerte participación interna, con 90,000 suscritos por los insiders Sheldon Kales y Dr. Rahul Kushwah (45,000 cada uno).

La empresa emitió 5,000,000 unidades a 0.02 CAD por unidad, con cada unidad compuesta por una acción común y un warrant de compra. Los warrants son ejercitables a 0.05 CAD por acción durante 24 meses, con una cláusula de aceleración si los precios de las acciones superan 0.10 CAD durante diez días de negociación consecutivos.

Además, Predictmedix ha comenzado la fabricación de quince Estaciones de Salud Inteligente AI para un despliegue estratégico, apuntando principalmente al mercado de Estados Unidos. Los ingresos apoyarán la expansión del mercado, con un enfoque en los sectores empresariales y gubernamentales de EE. UU.

Predictmedix AI (CSE: PMED, OTC: PMEDF)는 비중개 사모 배치의 세 번째이자 마지막 트랜치를 성공적으로 마감하며 100,000 CAD를 모금했습니다. 이번 배치에서는 내부자의 강력한 참여가 있었으며, 90,000이 내부자인 Sheldon Kales와 Dr. Rahul Kushwah에 의해 각각 45,000씩 구독되었습니다.

회사는 5,000,000 유닛0.02 CAD의 가격으로 발행했으며, 각 유닛은 하나의 보통주와 하나의 매입권으로 구성됩니다. 매입권은 24개월 동안 주당 0.05 CAD에 행사할 수 있으며, 주가가 10일 연속 거래일 동안 0.10 CAD를 초과할 경우 가속 조항이 적용됩니다.

추가로, Predictmedix는 미국 시장을 주 대상으로 하는 전략적 배치를 위해 15개의 스마트 헬스 AI 스테이션 제작을 시작했습니다. 수익금은 시장 확장을 지원하며, 미국 기업 및 정부 부문에 중점을 두고 있습니다.

Predictmedix AI (CSE: PMED, OTC: PMEDF) a réussi à clôturer la troisième et dernière tranche de son placement privé non médié, levant 100 000 CAD. Ce placement a connu une forte participation des initiés, avec 90 000 souscrits par les initiés Sheldon Kales et Dr. Rahul Kushwah (45 000 chacun).

La société a émis 5 000 000 d'unités à 0,02 CAD par unité, chaque unité étant composée d'une action ordinaire et d'un bon de souscription. Les bons sont exerçables à 0,05 CAD par action pendant 24 mois, avec une clause d'accélération si les prix des actions dépassent 0,10 CAD pendant dix jours de bourse consécutifs.

De plus, Predictmedix a commencé la fabrication de quinze Stations de Santé Intelligente AI pour un déploiement stratégique, ciblant principalement le marché américain. Les produits soutiendront l'expansion du marché, en se concentrant sur les secteurs d'entreprise et gouvernementaux des États-Unis.

Predictmedix AI (CSE: PMED, OTC: PMEDF) hat erfolgreich die dritte und letzte Tranche seiner nicht vermittelte Privatplatzierung abgeschlossen und 100.000 CAD gesammelt. Die Platzierung verzeichnete eine starke Insider-Beteiligung, wobei 90.000 von den Insidern Sheldon Kales und Dr. Rahul Kushwah (45.000 jeweils) gezeichnet wurden.

Das Unternehmen hat 5.000.000 Einheiten zu 0,02 CAD pro Einheit ausgegeben, wobei jede Einheit aus einer Stammaktie und einem Kaufwarrant besteht. Warrants können für 0,05 CAD pro Aktie über 24 Monate ausgeübt werden, mit einer Beschleunigungsklausel, wenn die Aktienkurse zehn aufeinanderfolgende Handelstage über 0,10 CAD steigen.

Zusätzlich hat Predictmedix mit der Herstellung von fünfzehn Smart Health AI Stationen für eine strategische Bereitstellung begonnen, die hauptsächlich auf den US-Markt abzielt. Die Erlöse werden die Marktexpansion unterstützen, mit einem Fokus auf die US-Unternehmens- und Regierungssektoren.

Positive
  • Strong insider confidence demonstrated through 90% participation in private placement
  • Manufacturing commenced for 15 Smart Health AI Stations
  • Strategic expansion into U.S. enterprise and government sectors
Negative
  • Low-price unit offering at $0.02 indicates potential share dilution
  • Small capital raise of only $100,000 may limit growth potential

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP) ("Predictmedix" or the "Company"), a leading provider in AI-powered health screening solutions, is pleased to announce the successful closing of the third and the final tranche of its non-brokered private placement, raising total gross proceeds of $100,000 CAD. Notably, $90,000 of the tranche was subscribed by insiders, with Sheldon Kales and Dr. Rahul Kushwah each participating for $45,000, highlighting strong internal confidence in Predictmedix’s future growth and innovation.

The Company issued 5,000,000 units (“Units”) at a price of $0.02 per Unit, raising $100,000 in this tranche. Each Unit consists of one common share of Predictmedix and one common share purchase warrant. Each full warrant (“Warrant”) entitles the holder to acquire an additional common share at $0.05 per share for a period of 24 months. However, if the volume-weighted average trading price of Predictmedix’s common shares on the CSE exceeds $0.10 for ten consecutive trading days (starting four months and one day after closing), the Company reserves the right to accelerate the warrant expiry date to no less than 30 days from the date of notice.

Additionally, Predictmedix is pleased to announce that fabrication of fifteen Smart Health AI Stations has commenced, with units planned for strategic deployment. These stations are set for strategic deployment, with a primary focus on the United States, where they will be showcased to targeted customers to accelerate market penetration and demonstrate the efficacy of Predictmedix’s AI-driven health management solutions. While the primary emphasis is on the U.S. market, the company may also deploy units in other regions as opportunities arise. Proceeds from the placement will be used to expand market opportunities, prioritizing growth in the U.S. across enterprise and government sectors.

Insiders’ participation in the Private Placement constitutes a “related party transaction” pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying on the exemption from the valuation and minority shareholder approval requirements under MI 61-101, as the fair market value of the Insiders’ participation in the Private Placement does not exceed 25% of the market capitalization of the Company.

All securities issued in connection with the private placement are subject to a statutory hold period of four months and one day from the date of issuance.

To receive company news, please sign up for alerts at the bottom of the page link below: https://predictmedix.com/press-releases/

About Predictmedix AI Inc.
Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company’s Smart Health AI Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI’s proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

Caution Regarding Forward-Looking Information:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Dr. Rahul Kushwah, COO

rahul@predictmedix.com

(647) 889 6916

Source: Predictmedix AI Inc.

FAQ

How much did Predictmedix AI (PMEDF) raise in its third tranche private placement?

Predictmedix AI raised $100,000 CAD in the third tranche, with $90,000 coming from insider participation.

What are the terms of PMEDF's warrant offering in the private placement?

Each warrant allows purchase of one common share at $0.05 for 24 months, with acceleration if share price exceeds $0.10 for 10 consecutive trading days.

How many Smart Health AI Stations is PMEDF manufacturing and where will they be deployed?

Predictmedix is manufacturing fifteen Smart Health AI Stations, primarily targeting deployment in the United States market.

What is the level of insider participation in PMEDF's recent private placement?

Insiders contributed $90,000 of the $100,000 raised, with Sheldon Kales and Dr. Rahul Kushwah each investing $45,000.
Predictmedix

OTC:PMEDF

PMEDF Rankings

PMEDF Latest News

PMEDF Stock Data

5.10M
125.63M
16.39%
Medical Devices
Healthcare
Link
Canada
Toronto